VENCLEXTA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VENCLEXTA (VENCLEXTA).
Selective inhibitor of B-cell lymphoma-2 (BCL-2) protein, restoring apoptosis in malignant cells.
| Metabolism | Primarily metabolized by CYP3A4; minor contribution from CYP3A5; substrate of P-glycoprotein. |
| Excretion | Primarily fecal (approximately 90% of absorbed dose), with <1% excreted renally as unchanged drug. Biliary excretion contributes to fecal elimination. |
| Half-life | Terminal elimination half-life is approximately 26 hours. Supports once-daily dosing with steady-state achieved within 3–5 days. |
| Protein binding | >99.9% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein). |
| Volume of Distribution | Approximately 13.7 L (not weight-based; corresponds to ~0.2 L/kg for a 70 kg adult). Indicates extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 40–60% under fasting conditions; increased by approximately 3- to 5-fold with a high-fat meal (not recommended due to variability). |
| Onset of Action | Oral: Onset of action (tumor lysis syndrome risk) within 6–8 hours after first dose; clinical response (e.g., reduction in peripheral blood lymphocytes in CLL) may be observed within days to weeks. |
| Duration of Action | Duration of therapeutic effect is continuous with daily dosing. Dosing interruptions lead to rapid decline in plasma concentrations (elimination half-life ~26h). Continuous administration required for sustained BCL-2 inhibition. |
VENCLEXTA (venetoclax) is administered orally. For chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): dose escalation schedule (Week 1: 20 mg daily; Week 2: 50 mg daily; Week 3: 100 mg daily; Week 4: 200 mg daily; Week 5+: 400 mg daily) in combination with obinutuzumab or rituximab. For acute myeloid leukemia (AML): 600 mg orally daily on Days 1-28 in combination with azacitidine or decitabine, or low-dose cytarabine, in 28-day cycles.
| Dosage form | TABLET |
| Renal impairment | For CLL/SLL: No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). For severe renal impairment (CrCl <30 mL/min) or dialysis: Reduce dose by 50% (e.g., target dose 200 mg daily after escalation); monitor for toxicity. For AML: No adjustment for mild to moderate renal impairment; severe impairment (CrCl <30 mL/min) not studied; use with caution and consider dose reduction. |
| Liver impairment | For CLL/SLL: Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% (e.g., target 200 mg daily after escalation). Child-Pugh C: Avoid use (not recommended). For AML: Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 400 mg daily (from 600 mg). Child-Pugh C: Avoid use. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; no approved dosing recommendations. Clinical trials ongoing; dosing based on body weight (e.g., for relapsed/refractory malignancies, starting doses of 20-400 mg/m² orally daily with escalation) may be used in investigational settings. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VENCLEXTA (VENCLEXTA).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., hematologic toxicity), breastfeeding is not recommended during treatment and for at least 1 week after last dose. |
| Teratogenic Risk | Venetoclax is embryotoxic and fetotoxic in animal studies. In humans, there are no adequate data; however, based on mechanism of action (BCL-2 inhibitor), there is potential for teratogenicity. First trimester: risk of major malformations cannot be excluded. Second and third trimesters: potential for fetal growth restriction and oligohydramnios. Use only if maternal benefit outweighs fetal risk. |
■ FDA Black Box Warning
Tumor lysis syndrome (TLS): Risk is highest during initial ramp-up phase; prophylactic measures and monitoring required.
| Serious Effects |
["Concomitant use with strong CYP3A inhibitors at initiation or during ramp-up phase","Concomitant use with strong CYP3A inducers"]
| Precautions | ["Tumor lysis syndrome (TLS) - dose escalation and monitoring required","Neutropenia - monitor blood counts","Infections - increased risk","Immunization - avoid live vaccines during and after treatment","Embryo-fetal toxicity - can cause fetal harm"] |
Loading safety data…
| Geriatric use | No specific dose adjustment based on age alone. Elderly patients (≥65 years) are included in clinical trials; dose selection based on renal function, hepatic function, concomitant medications, and comorbidities. Monitor for increased risk of tumor lysis syndrome and hematologic toxicities. |
| Fetal Monitoring | Monitor complete blood count (CBC) with differential throughout treatment. Assess for tumor lysis syndrome (TLS) with lab monitoring (potassium, uric acid, phosphorus, calcium, creatinine). During pregnancy, fetal ultrasound to assess growth and amniotic fluid volume; doppler studies if indicated. |
| Fertility Effects | Animal studies show no direct effects on fertility; however, venetoclax may impair male and female fertility based on its mechanism (apoptosis induction in germ cells). Clinical data are lacking; recommend fertility preservation counseling. |